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The landscape of cancer genetic counseling and testing is rapidly evolving. Genetic 
testing technology is improving, management guidelines are evolving, and genetic testing 
options are expanding. These frequent updates to the components of cancer genetics have 
increased the complexity of managing patient care over time. In particular, this raises 
questions on the duty to re-contact patients as new information becomes available. This 
study explored healthcare providers’ duty to re-contact through the interests and 
expectations of patients, including which circumstances warrant re-contacting, which 
healthcare provider is responsible for re-contacting the patient, and the preferred method 
of re-contacting. Physicians’ opinions on whether or not patients should be updated as 
well as the person responsible for updating were also explored. To answer the questions 
set forth in this study, we surveyed patients undergoing genetic counseling for a 
hereditary cancer condition and physicians who work with cancer genetic counselors. The 
study was limited by low response rate from patients, so no statistically significant results 
could be confirmed. However, both groups indicated re-contacting patients with updates 
was desirable and assigned a high level of responsibility to providers for delivering these 
updates to patients. The majority of patient participants believed the duty to keep patients 
informed fell primarily on the genetic counselor and preferred the genetic counselor to 
initiate contact. In contrast, physician participants indicated genetic counselors, referring 
physician, and a shared responsibility between these two providers most frequently as the 
responsible parties.  
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1.1 Hereditary Cancer Syndromes 
After age, a positive family history of cancer is the most significant risk factor for 
developing the disease (Armstrong, Eisen, & Weber, 2000). It is estimated that up to 10% 
of all cancers are hereditary, meaning there is a germline mutation in a cancer 
susceptibility gene that confers an elevated cancer risk (van der Groep, van der Wall, & 
van Diest, 2011). Oftentimes germline mutations in these genes result in a predictable 
phenotype allowing clinicians to assess an individual’s likelihood for developing specific 
cancers. Genetic testing can be performed to identify and diagnose individuals with 
hereditary cancer syndromes, and personalized management can be implemented to 
reduce the lifetime cancer risk and cancer-related mortality (Feliubadaló et al., 2013).  
Since genetic testing for hereditary cancer syndromes first became commercially 
available, our understanding and knowledge of hereditary cancers has grown. As of 1996, 
around a dozen cancer predisposing genes had been identified (Nelson, 1996). To date, 
germline mutations in over 49 genes have been associated with an increased cancer risk 
(Hall, Forman, Pilarski, Wiesner, & Giri, 2014). Each of these genes predisposes 
individuals to particular malignancies when a pathogenic mutation is present. In each 
case, the likelihood for developing cancer varies, with some mutations conferring up to 
an 80% or higher lifetime risk for developing the disease.  
The majority of genetic testing for hereditary cancer syndromes relates to breast 
and colon cancers. Hereditary breast cancer has been attributed to mutations in multiple 
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genes. The first major gene associated with the development of breast cancer was 
BRCA1, which was linked to a region on chromosome 17 through linkage analysis studies 
in 1990 and subsequently sequenced in 1994 (Hall et al., 1990). A second gene, named 
BRCA2, was linked to chromosome 13 in 1994 using the same technique, then later 
sequenced in 1995 (van der Groep et al., 2011). Mutations in either of the BRCA genes 
are responsible for a condition known as BRCA-Related Breast and Ovarian Cancer 
syndrome (NCCN, 2016), or formerly as Hereditary Breast and Ovarian Cancer 
syndrome (HBOC), which predisposes carriers to breast, ovarian, prostate, and pancreatic 
cancers. Inherited mutations in these genes confer up to a 50-85% lifetime risk of breast 
cancer in females and an 8% lifetime risk of breast cancer in males. The lifetime risk of 
developing ovarian cancer in females can be as high as 40%, while the likelihood of 
developing prostate cancer in males is also increased (Shiovitz & Korde, 2015). 
Additionally, the probability of developing pancreatic cancer is elevated in both sexes, 
especially with mutations in BRCA2. 
Along with BRCA1 and BRCA2, pathogenic mutations in four other genes (TP53, 
PTEN, STK11, and CDH1) confer a high risk for breast cancer (Shiovitz & Korde, 2015; 
Weischer, Bojesen, Tybjoerg-Hansen, Axelsson, & Nordestgaard, 2007). Similar to the 
BRCA genes, each of these is part of a distinct clinical syndrome.  
Mutations in the TP53 gene are causative for Li-Fraumeni syndrome (LFS). This 
condition predisposes individuals to breast cancer, soft-tissue sarcomas, bone cancer, 
brain tumors, leukemia, adrenocortical carcinomas, and other forms of cancer (Nelson, 
1996). Childhood cancers are also a common feature and occur in around 44% of carriers 
by the age of 18 years. In adulthood, the lifetime risk of developing breast cancer for 
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females with this syndrome is around 80%, and the chance of developing a soft tissue 
sarcoma is around 30% in both sexes (Bougeard et al., 2015). There is also a 40% chance 
of multiple primary tumors in individuals with LFS, which has been partly attributed to 
the individual’s sensitivity to chemotherapy and radiation used to treat the first tumor 
(Bougeard et al., 2015).  
PTEN Hamartoma Tumor syndrome (PHTS), also known as Cowden syndrome, 
is a condition associated with a higher incidence of breast, follicular thyroid, endometrial, 
and renal cancers, with the lifetime risks being as high as 80%, 35%, 28%, and 33%, 
respectively. There is an additional risk for colorectal cancers (9%) and melanoma (6%), 
and the risk of gastrointestinal hamartomas is increased (Tan et al., 2012; Ngeow, 
Sesock, & Eng, 2015). Peutz-Jeghers syndrome (PJS) is caused by a germline mutation in 
the STK11 gene. Individuals with this condition are at an increased risk for developing a 
variety of gastrointestinal tumors, and females have a 50% chance of developing breast 
cancer (Hearle et al., 2006; van der Groep et al., 2011). Mutations in the CDH1 gene 
cause a condition called Hereditary Diffuse Gastric Cancer syndrome (HDGC). Women 
with this condition have up to a 50% chance of developing breast cancer while the risk of 
gastric cancer is as high as 70% in males and 56% in females (Hansford et al., 2015; 
Stuckey & Onstad, 2015).  
In addition to these high-risk gene mutations, moderate risk genes have recently 
been introduced into clinical cancer genetic testing. These genes, ATM, BRIP1, PALB2, 
and CHEK2, each confer an estimated two-fold increase in female breast cancer risk and 
are considered to have moderate penetrance (Shiovitz & Korde, 2015). Together with the 
higher penetrance genes, mutations in these genes are responsible for the majority of 
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hereditary breast cancer cases in which a genetic cause can be identified (Shiovitz & 
Korde, 2015). 
Lynch syndrome, formerly known as Hereditary Non-Polyposis Colorectal 
Cancer syndrome (HNPCC), is one of the more common hereditary colon cancer 
syndromes. Individuals with Lynch syndrome are more susceptible to colorectal, 
endometrial, ovarian, stomach, and other cancers. This condition is caused by mutations 
in MLH1, MSH2, MSH6, PMS2, or EPCAM. Depending upon the gene in which the 
mutation is found, individuals with Lynch syndrome have anywhere from a 10-80% 
lifetime risk of developing colon cancer, a 15-60% lifetime risk of endometrial cancer, a 
1-13% lifetime risk of stomach cancer, a 1-25% lifetime risk of ovarian cancer, and an 
elevated risk for hepatobiliary tract, urinary tract, small bowel, brain, sebaceous 
neoplasms, and pancreatic cancers (Barrow et al., 2009; NCCN, 2015).  
An elevated colon cancer risk is a feature of hereditary polyposis syndromes as 
well. Familial Adenomatous Polyposis syndrome (FAP) carries close to a 100% lifetime 
risk for colon cancer and an increased risk for duodenal, pancreatic, and papillary thyroid 
cancers. There is an additional risk for hepatoblastomas and medulloblastomas during 
childhood (Hampel, Bennett, Buchanan, Pearlman, & Wiesner, 2015). FAP is caused by 
mutations in the APC gene. Juvenile Polyposis syndrome (JPS) is another hereditary 
polyposis syndrome with a 40% to 50% lifetime risk for colon cancer. This condition, 
which is caused by mutations in the SMAD4 and BMPR1A gene, also raises the risk for 
stomach cancer up to 21% and notably increases the risk for other gastrointestinal cancers 
(NCCN, 2015; Hampel et al., 2015).  
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Other genes, beyond those mentioned above, have been linked to hereditary 
cancer. The features and associated cancer risks for some of these conditions are well-
defined, while the implications of other pathogenic mutations are less appreciated. 
However, research on the genetics of inherited cancer is ongoing, and clinical 
understanding of hereditary cancer is emergent. The future of hereditary cancer genetics 
will look different than the current landscape described.  
1.2 Management 
For many of the currently well-characterized hereditary cancer syndromes, 
guidelines are in place for mutation-based cancer screening and management purposes. 
These recommendations are often based on the consensus statements of the National 
Comprehensive Cancer Network (NCCN), which has established guidelines on many of 
the well-defined hereditary cancer syndromes such as BRCA-Related Breast and Ovarian 
Cancer syndrome, LFS, PHTS, PJS, HDGC, Lynch, FAP, and JPS (NCCN, 2015). In 
accordance with our expanding knowledge of cancer genetics, NCCN has also started to 
develop guidelines defining which moderate risk genes warrant further consideration 
regarding protocols for high-risk breast screening and/or risk-reducing surgeries (NCCN, 
2016).  
The results of genetic testing can significantly impact patient care. For example, 
in women with a mutation in either BRCA1 or BRCA2, NCCN (2015) recommends 
beginning breast surveillance at an earlier age. In the general population within the 
United States, women are screened for breast cancer by annual mammograms beginning 
at 40 years of age. Comparatively, NCCN recommends women with a BRCA1 or BRCA2 
mutation begin either annual breast MRIs or annual mammograms between the ages of 
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25-29 years (2015). Screening is further increased in female mutation carriers who are 30 
years of age or older to include alternating between mammograms and breast MRIs every 
six months. NCCN also recognizes that for some women with a mutation, the more 
appropriate choice may be to opt for a prophylactic bilateral mastectomy.  
Surveillance for ovarian cancer in women with a mutation in BRCA1 or BRCA2 
can be performed by transvaginal ultrasounds or serum CA-125. However, these 
screening options are poor tools for the detection of ovarian cancer. The most recent 
NCCN guidelines recommend against screening for ovarian cancer in favor of a risk-
reducing bilateral salpingo-oophorectomy (BSO), typically performed between 35 and 40 
years of age or upon completion of child bearing (NCCN, 2016). An additional benefit of 
a BSO is that it reduces the risk of breast cancer by 50% in women with this condition if 
performed prior to menopause (NCCN, 2016). 
Lynch syndrome is another example of a hereditary cancer syndrome in which 
well-established management guidelines have been developed. NCCN (2015) 
recommends individuals with this condition begin colonoscopy screenings at the age of 
20-25 years. These should be repeated every one to two years to screen for colorectal 
cancer. Additionally, a prophylactic hysterectomy and BSO is a risk-reducing option that 
should be discussed with women with Lynch syndrome who have completed childbearing 
(NCCN, 2015). 
NCCN guidelines have not established testing criteria and/or management 
recommendations for every cancer predisposing gene, and it is less clear how to manage 
pathogenic mutations in some of the moderate risk genes. This does not nullify or 
decrease the utility of testing for mutations in such genes since in many cases, the results 
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may still be clinically actionable (Desmond et al., 2015). One specific example of this 
includes the BRIP1 gene. As recently as March 2016, NCCN has come out with new 
recommendations for the consideration of risk-reducing BSO in women who carry a 
mutation in this gene. However, there is currently no defined criteria for BRIP1 testing 
(NCCN, 2016) which is currently offered as part of a multigene panel test. Evidence-
based guidelines are an important aspect of genetic testing and are meant to characterize 
genes in which mutations are clinically actionable. Therefore, these guidelines can 
support the need for genetic testing, especially to health insurance companies (Domchek, 
2015). 
Additionally, family history can impact cancer risk assessment and 
recommendations for clinical care. When there is a known familial mutation, family 
history-based recommendations might not be appropriate or necessary for all family 
members. Similarly, it is important to recognize the significance of identifying 
individuals with negative testing results in whom recommendations may be impacted 
based on family history alone.  
In conjunction with consensus statements from NCCN, guidelines from other 
professional societies, such as the American Cancer Society (ACS) and the American 
College of Obstetricians and Gynecologists (ACOG), can be used to determine a high-
risk breast screening protocol or the frequency of colon screening for example (Smith et 
al., 2016; Printz, 2016; Smith et al., 2015). Some differences exist between the 
recommendations from different societies. For example, there are minor variations in the 
age at which to begin screening, the frequency of screening, and other aspects. Overall 
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however, recommendations are generally consistent. Most importantly, guidelines are 
updated on a regular basis to keep pace with the ever-changing clinical environment.  
1.3 Evolution of Genetic Testing Technology 
Genetic testing was first introduced into clinical practices in the mid-1990s. The 
earlier approaches involved sequence analysis (Lynch, Snyder, Shaw, Heinen, & 
Hitchins, 2015) by Sanger sequencing to detect deleterious point mutations, small 
deletions, and small insertions within one to two single genes. Sanger sequencing has 
long been considered the gold standard for genetic testing and has been the traditional 
technology used for the detection of DNA-based mutations. However, since genetic 
testing for hereditary cancer syndromes first became commercially available, there has 
been exponential growth in both the methodology with which we test for gene mutations 
and our knowledge about their implications.  
Although Sanger sequencing still has a prominent role in the laboratory, other 
techniques have since been developed to detect a wider array of deleterious gene 
mutations. Two such techniques, called quantitative multiplex PCR of short fluorescent 
fragments (QMPSF) and multiplex ligation-dependent probe amplification (MLPA) have 
been applied to identify large genomic deletions and duplications within the BRCA1 
gene. Using QMPSF, Casilli et al. (2002) identified two previously unreported mutations. 
The first novel mutation was a large deletion of exons 1-22. This individual had a 
personal history of breast and ovarian cancer and two affected first-degree relatives: one 
with breast cancer, the other with ovarian cancer. The other novel mutation, a deletion of 
exons 15-16, was detected in an individual with a family history of breast and ovarian 
cancer. In addition to these large deletions, three genomic rearrangements were detected 
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in this study. Another study by Hogervorst et al. (2003) analyzed 805 families with a 
history of breast and/or ovarian cancers and found pathogenic BRCA1 mutations in 144 
families using Sanger sequencing. The remaining 661 families with no identified 
mutations were then analyzed for large deletions using MLPA, and mutations in five 
additional families were detected.  
Genomic rearrangements were originally believed to comprise a small percentage 
of the total number of cancer-predisposing mutations. Studies such as the ones by Puget 
et al. (1999) and Montagna et al. (2003) aimed to address the mutational spectrum and 
frequencies of the BRCA1 gene, and these studies had variable results. In the study by 
Montagna et al. (2003), large genomic rearrangements accounted for more than 30% of 
the BRCA1 mutations in an Italian cohort, while the Puget et al. (1999) study observed 
the proportion of large genomic rearrangements accounted for 8% of BRCA1 mutations in 
a cohort of American families. From these and other similar studies, it is concluded that 
the proportion of genomic rearrangements responsible for any given hereditary cancer 
syndrome is dependent upon the gene and population in question, and there can be 
significant genetic variation from one population to the next.  
The strategies for the detection of pathogenic mutations have continued to evolve. 
The latest technology currently being integrated into commercial genetic testing is next 
generation sequencing (NGS). NGS has the ability to potentially detect variants missed 
by traditional methods (D’Argenio et al., 2015), is more cost effective, and has a quicker 
turn-around time. Unlike traditional molecular testing methods, NGS is capable of 
analyzing multiple genes at one time, which has enabled genetic testing to evolve into 
multigene panel tests. This is significant, as other genes beyond BRCA1 and BRCA2 are 
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implicated in hereditary cancer syndromes, and additional cancer susceptibility genes 
with overlapping phenotypes are emerging. In fact, breast cancer is an overlapping 
feature of multiple hereditary cancer syndromes as discussed earlier (Doherty, Bonadies, 
& Matloff, 2015).  
Risk assessment and management may be significantly impacted when newer 
technology and additional genes are incorporated into genetic testing. For example, in a 
study by Walsh and colleagues (2006), breast cancer families with prior negative BRCA1 
and BRCA2 test results were analyzed for large genomic arrangements in the BRCA 
genes, as well as for mutations in three other genes related to hereditary breast cancer: 
CHEK2, TP53, and PTEN. Researchers observed that 17% of participants with no 
previously detected mutations in either BRCA1 or BRCA2 actually had a pathogenic 
mutation in one of the analyzed genes, including 12% with large genomic rearrangements 
in a BRCA gene. The remaining 5% had a mutation in CHEK2, TP53, or PTEN.  
The study by Walsh et al. (2006) demonstrates the limitation of single gene 
analysis by Sanger sequencing alone and supports including deletion and duplication 
testing with single gene analysis. It also provides evidence for the utility of a multigene 
panel during risk assessment and genetic counseling. This testing approach is consistent 
with the National Society of Genetic Counselors (NSGC) practice guidelines (Berliner, 
Fay, Cummings, Burnett, & Tillmanns, 2013), which recommend that risk assessment 
and genetic counseling for individuals with a personal and/or family history of breast 
cancer should include the consideration of other hereditary cancer syndromes and genes 
in which breast cancer is a component. In fact, multigene panel testing that includes 
around two dozen different genes “represent a substantial (>40%) increase diagnostic 
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yield of risk-associated mutations compared to BRCA1/2 testing alone” when BRCA-
Related Breast and Ovarian Cancer syndrome is suspected (Desmond et al., 2015, p. 
949). Furthermore, multigene panel testing results are “likely to change clinical 
management” in a substantial amount of individuals, making the results of testing 
clinically actionable (Desmond et al., 2015, p. 943). Individuals with strong family 
histories of cancer who underwent genetic testing while it was in its early stages and 
found no causative genetic mutation may benefit from a multigene panel.  
1.4 Clinical Genetic Testing Timeline 
The availability of genetic testing for hereditary cancer syndromes over the years 
warrants further consideration when reviewing the changing landscape of cancer genetics 
in the clinical setting. The evolutionary trajectory of testing has been influenced by both 
the scientific achievements mentioned above and political disputes, with the latter 
proving to be a limiting factor on the advancement and accessibility of testing. This is 
mainly attributed to Supreme Court rulings in the early to mid-1990s, which granted a 
series of patents covering human genes to various companies. This most significantly 
relates to patents that were granted over the BRCA1 and BRCA2 genes to a company 
called Myriad Genetics Inc., which gave them exclusive rights over the BRCA genes, 
mutations in these genes, and the diagnostic tests in which these mutations could be 
identified (Gold & Carbone, 2010).  
Historically, genetic testing for hereditary cancer syndromes focused heavily on 
breast cancer because of its high prevalence in the general population and availability of 
families for research protocols. Myriad’s patents allowed them to become the first 
company to market and benefit from commercial genetic testing of BRCA1 and BRCA2. 
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In late 1996, the company introduced three principal diagnostic tests: 1) Comprehensive 
BRACAnalysis, which sequenced the entire BRCA1 and BRCA2 genes, 2) Single Site 
BRACAnalysis, used for detecting a specific familial mutation, and 3) Multisite three 
BRACAnalysis, which was designed to detect three specific mutations which have been 
observed at a higher frequency in the Ashkenazi Jewish population (Gold & Carbone, 
2010).  
Myriad’s initial tests were not able to identify all mutations in the BRCA1 and 
BRCA2 genes, specifically large genomic rearrangements (Gold & Carbone, 2010). To 
keep up with technological advancements, the company came out with a newer version of 
their Comprehensive BRACAnalysis test in 2002, which incorporated the five most 
common large rearrangements in the BRCA1 gene (Myriad Genetics, 2002). This test was 
later replaced by Myriad’s BRACAnalysis Large Rearrangement Test (BART) in 2006, 
which can detect large genomic rearrangements in both BRCA1 and BRCA2.  
As research and technology progressed, the implication of other genes beyond 
BRCA1 and BRCA2 in the development of hereditary cancer began to receive more 
attention. Testing approaches began to shift from single gene testing to the simultaneous 
analysis of multiple genes with the development of NGS. The first widely available 
multigene panel test for hereditary breast cancer was introduced in 2012 by Ambry 
Genetic Laboratories (Lundy, Forman, Valverde, & Kessler, 2014), enabling the 
possibility of analyzing multiple genes at once for the first time. However, at this time 
Myriad still held exclusive rights over BRCA1 and BRCA2 genetic testing and as a result, 




Opinions surrounding the ethics of gene patenting had been circulating since the 
patents were first issued. Societies such as the American College of Medical Genetics 
(ACMG) expressed concerns that gene patents “limited the accessibility of competitively 
priced genetic testing services and hinder[ed] test-specific development of national 
programs for quality assurance” (ACMG, 1999, p. 237). These concerns were not 
unwarranted. One leading example of this relates to the availability of comprehensive 
testing for the BRCA genes. Deletion and duplication analysis was not routinely included 
in all BRCA testing until 2013 despite the introduction of BART in 2006 (Myriad 
Genetics, n.d.). BART had to be ordered separately and was not typically covered by 
insurance (Shannon et al., 2011). At this time other commercial laboratories were 
standardly offering deletion and duplication analysis for all genes that were sequenced. 
However, due to the gene patents, patients seeking BRCA testing did not have a choice in 
laboratory. 
Following a few years of turmoil and controversy, the Supreme Court overturned 
its ruling on gene patents in 2013, stating that patents could not be obtained on DNA 
segments because they are a product of nature (Cook-Deegan & Niehaus, 2014). This has 
enabled other laboratories to perform BRCA1 and BRCA2 testing and to include these 
genes on their hereditary cancer panels. This, along with the advent of NGS, has led to a 
decrease in the cost of genetic testing. Furthermore, it is suspected that the cost of testing 
has an impact on guideline stringency. A decrease of cost could have a trickle down 
affect allowing more people to have access to genetic testing (Meldrum, Doyle, & 
Tothill, 2011). Therefore, someone who did not meet genetic testing criteria based on 
earlier guidelines may do so now or in the future.  
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1.5 Duty to Re-contact 
The above scenarios illustrate the ever-changing landscape of what genetic testing 
can accomplish. However, in some situations these advancements in testing also raise 
ethical, legal, and practical concerns. In particular, this raises questions on the duty to re-
contact patients as new information becomes available. The duty to re-contact is defined 
in the genetics arena as the “ethical and/or legal obligation to re-contact former patients 
about new genetic information” (Otten et al., 2015). In cancer genetics, situations in 
which the duty to re-contact patients may become a concern include but are not limited to 
1) when a hereditary predisposition had been suspected, but no diagnosis had been made 
using previous testing techniques, and a new diagnostic test has become available 
(Fitzpatrick, Hahn, Costa, & Huggins, 1999); 2) when a change in cancer screening and 
management guidelines occurs; and 3) when insurance guidelines change to allow for 
additional genetic testing.  
The only policy statement addressing the duty to re-contact genetics patients was 
issued by ACMG in 1999 (ACMG, 1999). According to the statement, the referring 
physician, primary care provider, and patient should receive a written summary of the 
appointment from the genetics provider, which should include the recommendation to 
inquire about updates in the future. Additionally, it states the primary care provider is 
responsible for encouraging the patient to inquire about updates and re-contact genetics 
when needed. Therefore, the patient needs to be aware of his or her duty to re-contact. No 




In many situations, it is not practical to re-contact all former patients. Barriers 
such as the amount of staff time required to re-contact every single patient ever seen at 
that particular clinic and tracking down patients who have changed address or telephone 
number are often cited as limitations. Furthermore, in the genetics arena the service 
provider often acts as a consultant, and the relationship between provider and patient is 
not intended to be longitudinal (Fitzpatrick et al., 1999).  
Previous research on this topic has found that patients with colon cancer who 
underwent genetic counseling desired highly personalized updates (Griffin et al., 2007). 
The vast majority, 90% of those surveyed, indicated that it was the healthcare provider’s 
responsibility to keep patients informed. The provider that was most frequently expected 
to keep patients updated was the genetics provider (65%), followed by the primary care 
physician and gastroenterologist. When asked how often patients should be re-contacted, 
participants were evenly divided among three categories: “only when new discoveries are 
made that pertain directly to the re-contacted patient,” “when any new discoveries are 
made,” and “regularly, even if no new discoveries are made.”  
Although, as previously discussed, statements and research on the duty to re-
contact exists, there has been no attempt to refine these statements and add to the research 
following the Supreme Court ruling on gene patents. Since this time, the prices of testing 
have dropped. NGS has emerged as the prominent technology, and large panel tests are 
becoming routine in hereditary cancer clinics. For these reasons, it is worthwhile to 
readdress the duty to re-contact former genetics patients, especially from a hereditary 
cancer standpoint.  
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   1.5.1 Ethical Perspective. In hereditary cancer genetic counseling, it is not currently a 
standard of care to re-contact patients when there is new and relevant information or 
when newer diagnostic testing options become available. Many arguments from different 
ethical viewpoints, both in favor of and against re-contacting, have been made in the 
literature. The arguments focus mainly around three principles in healthcare: respect for 
patient autonomy, beneficence (do good), and nonmaleficence (do no harm) (Otten et al., 
2015).  
It has been argued that providing information to patients promotes autonomy by 
allowing these individuals to make informed decisions about their healthcare. By this 
argument, re-contacting patients when new and relevant information becomes available is 
indicated. In fact, many genetics providers believe that although it is not practical, re-
contacting is desirable since it provides patients with the best care (Fitzpatrick et al., 
1999), which falls under the principle of beneficence. However, respect of autonomy also 
includes the patient’s right to remain uniformed (Hunter, Sharpe, Mullen, & Meschino, 
2001). In some scenarios re-contacting may actually have the potential to cause harm to 
patients, which goes against the principle of nonmaleficence. For example, the decision 
about whether or not to undergo genetic testing for a hereditary cancer syndrome is made 
based on information provided at the time of the patient’s appointment, and he or she 
may not desire to readdress the topic at a later point. In this situation, re-contacting a 
patient several years following an appointment may cause renewed anxiety for an issue 
that had already been laid to rest (Hunter, 2001). 
Overall, there is a general consensus that there are both potential benefits and 
harms to re-contacting former patients. Information affects people differently. The type 
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of information being provided and the timing of such information likely influence the 
benefit or harm (Otten et al., 2015). Because of the potential emotional and psychological 
impact re-contacting may have, this is an avenue that would benefit from further 
exploration.  
   1.5.2 Legal Perspective. When examining the duty to re-contact former patients from a 
legal perspective, liability is a major concern. One argument supporting the practice of 
re-contacting former patients is that providers cannot be held liable for negligence for not 
providing updated information that may be medically relevant or actionable (Otten et al., 
2015). In the past, providers have been held liable for failure to disclose subsequently 
discovered information about risks and side effects of medications and medical devices to 
former patients. However, there is currently no legal precedent requiring a complete 
disclosure of future knowledge pertaining to genetics (Hunter et al., 2001). Other 
arguments regarding the legal obligation to re-contact former patients state liability as a 
concern. In this argument, genetics service providers would be vulnerable to malpractice 
lawsuits if this duty was not fulfilled. Therefore, this obligation might not be in the best 
interests of the service providers (Otten et al., 2015). Furthermore, re-contacting may also 
go against a patient’s desire or right to remain uniformed.  
   1.5.3 Current Landscape of Re-contacting. There is currently no consensus among 
professionals about whether or not patients should be re-contacted and, if so, how this 
should be accomplished. The only published guideline to date is the ACMG policy 
statement referenced previously (ACMG, 1999). A recent study aimed to address whether 
or not re-contacting was occurring and how it was being implemented in a population of 
genetic service providers in the United Kingdom (Carrieri et al., 2016). The majority of 
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participants in this study indicated they had experience with re-contacting but did not do 
so on a regular basis. They also did not routinely obtain consent from patients prior to re-
contacting. The participating genetic service providers were most likely to re-contact 
patients if the information was viewed as clinically actionable. This included the 
availability of new diagnostic tests, new management guidelines, and reclassification of 
previous test results. Although the majority indicated they had updated patients with new 
information at some point, few stated their clinics had developed a system for re-
contacting. Additionally, some participants stated they contacted the primary care 
provider with updated information while others contacted the patient directly.   
 No consensus exists between providers regarding which person is responsible for 
keeping patients informed (Otten et al., 2015). Cancer genetic evaluations typically 
involve one to three visits with a genetic counselor within a short period of time and 
include a risk assessment prior to testing (Riley et al., 2012). Long-term follow-up 
appointments are unusual, and no long-term patient-provider relationship is expected. 
This is different than other specialties where patients may get re-evaluated for the same 
condition on a regular basis. Especially in cancer genetics, it is unclear when a re-
assessment needs to be made and by whom. Current healthcare practices are moving in 
the direction of interdisciplinary teams working together to provide patient care. This has 
further led to the question of whom, if anyone, bears the responsibility to re-contact 
patients. Is it the primary care physician who has an ongoing relationship with the 
patient; the referring physician who may only be working as a temporary specialist in the 
patient’s care; or the genetic counselor who may be acting only as a consultant? Or is it 
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the patient’s responsibility for maintaining the patient-provider relationship and actively 
inquiring about updates that affect medical management?  
Many questions remain unanswered pertaining to the duty to re-contact patients 
regarding new genetic information, services, or insurance coverage. These questions are 
practical, legal, and ethical in nature. The purpose of the current study is to explore some 
of these questions surrounding the duty to re-contact, particularly through the interests 
and expectations of patients receiving genetic counseling and testing for hereditary 
cancer syndromes and the attitudes of physicians involved in their care. The intention is 
to elicit patient opinions on which circumstances warrant re-contacting, which healthcare 
provider should re-contact the patient, and the preferred method of re-contacting. An 
additional goal is to determine if there are common themes among patient and physician 





Re-contacting Cancer Genetic Counseling Patients:  
Expectations of Patients and Physicians1 
 
2.1 Abstract 
The landscape of cancer genetic counseling and testing is rapidly evolving. Genetic 
testing technology is improving, management guidelines are evolving, and genetic testing 
options are expanding. These frequent updates to the components of cancer genetics have 
increased the complexity of managing patient care over time. In particular, this raises 
questions on the duty to re-contact patients as new information becomes available. This 
study explored healthcare providers’ duty to re-contact through the interests and 
expectations of patients, including which circumstances warrant re-contacting, which 
healthcare provider is responsible for re-contacting the patient, and the preferred method 
of re-contacting. Physicians’ opinions on whether or not patients should be updated as 
well as the person responsible for updating were also explored. To answer the questions 
set forth in this study, we surveyed patients undergoing genetic counseling for a 
hereditary cancer condition and physicians who work with cancer genetic counselors. The 
study was limited by low response rate from patients so no statistically significant results 
could be confirmed. However, both groups indicated re-contacting patients with updates 
was desirable and assigned a high level of responsibility to providers for delivering these 
                                                 




updates to patients. The majority of patient participants believed the duty to keep patients 
informed fell primarily on the genetic counselor and preferred the genetic counselor to 
initiate contact. In contrasts, physician participants indicated genetic counselors, referring 
physician, and a shared responsibility between these two providers most frequently as the 
responsible parties.  
2.2 Introduction 
 The most significant risk factor for developing cancer excluding age is a positive 
family history of the disease. It is estimated up to 10% of all cancers are hereditary, 
meaning there is a germline mutation in a gene that confers an elevated cancer risk (van 
der Groep et al., 2011). In certain cases, the likelihood of developing cancer is greater 
than 80%. Genetic testing can have a significant impact on mutation carriers since 
management recommendations can be personalized to reduce cancer risk and cancer-
related mortality (Feliubadaló et al., 2013). Mutation-based recommendations for 
screening and management purposes are made according to consensus guidelines 
developed by professional societies such as the National Comprehensive Cancer Network 
(NCCN), which formulate these guidelines based on current literature and professional 
opinions, and the guidelines are updated on an annual basis. However, the landscape of 
cancer genetics is rapidly evolving. The last few decades have seen an exponential 
growth in our understanding and knowledge of hereditary cancers, and an increasing 
number of cancer susceptibility genes are emerging. Furthermore, advancements in 
genetic testing technology have improved the sensitivity and reliability of these 
diagnostic tests (D’Argenio et al., 2015). While these factors have led to improved patient 
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care, frequent updates to the components of cancer genetics increases the complexity of 
caring for patients over time. 
Genetic testing for mutations in cancer susceptibility genes was first incorporated 
into clinical practices around 1995 (Nelson, 1996). Testing at this time primarily focused 
on hereditary breast cancer and employed a single gene analysis strategy. Current genetic 
testing trends have evolved to include a broader approach when attempting to identify 
mutations in cancer susceptibility genes. Next Generation Sequencing (NGS) is the latest 
technology being widely integrated into clinical practices due to its ability to analyze 
multiple genes simultaneously and its improved detection rate. NGS has allowed the 
introduction of multigene panel tests, which is significant, as an increasing number of 
genes are being implicated in hereditary cancer syndromes, and additional cancer 
susceptibility genes with overlapping phenotypes are emerging.  
Multigene panel tests were introduced into the clinical setting in 2012 (Lundy et 
al., 2014). At the time panel tests were introduced, laboratories were limited by which 
genes could legally be included on their cancer panels. This was a direct result of gene 
patents that were granted to various laboratories in the early to mid-1990s (Gold & 
Carbone, 2010). While these patents were upheld, patients who desired genetic testing for 
certain hereditary cancer conditions were required to go through the laboratory that 
owned the patents. In 2013, patents on human genes were overturned by the Supreme 
Court (Cook-Deegan et al., 2014). This has enabled other laboratories to include 
previously patented genes on their hereditary cancer panels, meaning patients and their 
genetics healthcare providers now have more choices on laboratory when ordering testing 
of cancer susceptibility genes.  
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Now that genetic testing technologies have improved and testing options have 
expanded and become more affordable, individuals with strong family histories of cancer 
who underwent genetic testing while it was in its early stages and found no causative 
genetic mutation may benefit from further testing. Genetic testing that examines a greater 
number of genes with a higher detection rate is beneficial for providing more 
personalized care since it has the potential to significantly impact risk assessment and 
management (Desmond et al., 2015). However, in some situations updates to the 
components of cancer genetic testing also raise ethical, legal, and practical concerns.  
With continued advancements in genetic technology, the duty to re-contact 
patients as new information becomes available has been a major question plaguing 
clinicians. The duty to re-contact is defined in the genetics arena as the “ethical and/or 
legal obligation to re-contact former patients about new genetic information” (Otten et 
al., 2015). In cancer genetics, situations in which the duty to re-contact patients may 
become a concern include but are not limited to 1) when a hereditary predisposition had 
been suspected, but not discovered using previous testing techniques, and a new 
diagnostic test has become available (Fitzpatrick et al., 1999), 2) when a change in cancer 
screening and management guidelines occurs, and 3) when insurance guidelines change 
to allow additional genetic testing. Because of the potential emotional and psychological 
impact re-contacting may have, this is an avenue that would benefit from further 
exploration.  
Additionally, current healthcare practices are moving in the direction of 
interdisciplinary teams working together to provide patient care. This has led to the 
question of who, if anyone, bears the responsibility to re-contact patients. Is it the 
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primary care physician, who has an ongoing relationship with the patient; the referring 
physician, who may only be working as a temporary specialist in the patient’s care; or the 
genetic counselor, who may be acting only as a consultant? Or is it the patient’s 
responsibility for maintaining the patient-provider relationship and actively inquiring 
about updates that affect medical management?  
Previous research on this topic has attempted to address these and other questions. 
Overall, re-contacting patients with updated knowledge is deemed desirable by genetic 
service providers (Fitzpatrick et al., 1999) and is something that is currently being 
practiced, albeit on an irregular basis (Carrieri et al., 2016). Genetic service providers 
have indicated the responsibility of staying informed about advancements in genetics is 
shared between the patient and the genetic service provider as well as other healthcare 
professionals (Fitzpatrick et al., 1999). In a policy statement published by the ACMG, the 
primary care provider was indicated as the main liaison between patient and genetics 
provider due to the ongoing nature of their relationship, although the primary care 
provider was also to encourage the patient to independently inquire about updates as 
needed (ACMG, 1999). However, in a study which surveyed patients with colon cancer, 
participants indicated that it was the healthcare provider’s responsibility to keep patients 
informed. These patients also indicated that they desired highly personalized updates 
(Griffin et al., 2007). 
The purpose of this study was to explore the duty to re-contact, particularly 
through the interests and expectations of patients receiving genetic counseling and testing 
for hereditary cancer syndromes, and the attitudes of physicians involved in their care. 
The intention was to elicit patient opinions on which circumstances warrant re-
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contacting, which healthcare provider should primarily be responsible for re-contacting 
the patient, and the preferred method of re-contacting. An additional goal was to 
determine if there were common themes among patient and physician perspectives.  
2.3 Materials and Methods 
   2.3.1 Participants. The study was targeted at adults who had undergone genetic 
counseling for a hereditary cancer condition and physicians who work with genetic 
counselors as either referring physicians or as part of tumor boards. 
 Individuals were referred to a genetic counselor for a suspicious personal and/or 
family history of a hereditary cancer condition. Any patient who met with a cancer 
genetic counselor at the University of South Carolina between November 2015 and 
February 2016 and at the Greenville Hospital System between January 2016 and 
February 2016, either for an initial visit or for a follow-up results appointment, were 
invited to participate in the study if they met the inclusion criteria. The inclusion criteria 
for participation included patients who were 18 years of age or older, English speaking, 
and individuals with recognized competence to read and understand the written material. 
Undergoing genetic testing was not a requirement for participation.  
Physicians associated with Palmetto Health Richland Hospital and Palmetto 
Health Baptist Hospital, both in Columbia, SC, were invited to participate in the study. 
The following physician specialties were targeted: oncology, surgery, 
obstetrics/gynecology (OB/Gyn), and primary care. These specialties were chosen since 
they are common referral sources to cancer genetic counseling.  
   2.3.2 Study Methods. Participation in this study entailed completing a questionnaire. 
The patient questionnaires were different from questionnaires provided to physicians.  
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Patients who were eligible to participate were informed of the study at the end of 
their genetic counseling session and were given an invitational letter (See Appendix A) 
by their genetic counselor. At that time, participants were also given a print copy of the 
questionnaire (See Appendix B) to be taken home and returned to our center via a self-
addressed postage-paid envelope.  
The patient questionnaire consisted of nineteen questions designed to assess 
participants’ opinions regarding re-contacting. A section of Likert scale questions was 
used to assess patients’ responses on which circumstances warrant re-contacting. 
Scenarios for re-contacting included the availability of newer diagnostic test options, 
when new research indicated a change in lifetime risk for developing cancer, when 
updates to testing results occurred, and following changes or updates to medical 
management or insurance guidelines. These Likert scale questions used a 1 to 4 scale of 
Strongly Disagree to Strongly Agree. Multiple choice questions were used to elicit 
opinions on which healthcare provider is primarily responsible for re-contacting the 
patient, the desired frequency and time period of re-contacting, and the preferred method 
of being updated. Basic demographic information was collected regarding the 
participants’ age range, sex, reasons for being referred to cancer genetic counseling, 
whether or not they had had genetic testing, and which provider referred them to genetic 
counseling.  
Print copies of the physician questionnaire were handed to every person that 
attended two breast and one gastric tumor boards. Tumor boards are multidisciplinary 
conferences where ongoing cancer cases are presented to establish and confirm treatment 
plans between various physician and non-physician specialists. Print copies were also 
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handed to all members at an obstetrical case conference, which are similarly attended by 
physician and non-physician specialists. Questionnaires at all meetings were completed 
and returned on site.  
The physician questionnaire (See Appendix C) consisted of five multiple choice 
questions designed to assess the opinions of physicians regarding which circumstances, if 
any, warrant re-contacting and which healthcare provider is primarily responsible for 
updating patients with new information. Demographic information was collected 
regarding the participants’ specialty, whether or not they had ever referred patients to a 
cancer genetic counselor, and whether or not they had ever personally updated patients 
with new information.  
No personal identifying information was collected for either group of participants. 
Approval for this research study was obtained through the Institutional Review Board, 
Office of Research Compliance, of the University of South Carolina, Columbia, SC, in 
November, 2015 and through the Institutional Review Board, Office of Research 
Compliance, of the Greenville Health System, Greenville, SC, in January, 2016.  
   2.3.3 Data Analysis. Descriptive statistics including response frequencies and 
percentages were analyzed for both groups using SPSS, Version 23.0.0.2.  
   2.3.3.1 Patients. Demographic questions collected information from the patients 
regarding their sex, age range, whether or not genetic testing had been performed, referral 
process to genetic counseling, and personal and/or family history of cancer.  
Descriptive statistical analyses were performed to provide data on demographic 
questions and response frequencies to the section of Likert scale questions inquiring 
about which circumstances warrant re-contacting. Response frequencies and percentages 
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were also calculated for multiple choice questions pertaining to how often and for what 
length of time participants indicated a desire to be re-contacted, the provider responsible 
for updating patients, and their preferred method of re-contacting. Additional 
comparisons were made between participants with a personal history of cancer with those 
who were unaffected to evaluate for any differences between the two groups with respect 
to participants’ desired frequency of re-contacting and the time period in which they 
desired updates. Tables and charts were created to illustrate response frequencies and 
percentages to various questions.  
   2.3.3.2 Physicians. Demographic information regarding physician specialty, referral 
history to cancer genetic counseling, and previous experience with updating patients with 
new and relevant genetic information was collected from the physicians.  
Response frequencies and percentages were provided for demographic 
information and multiple choice questions regarding physician opinions on 1) whether or 
not patients should be re-contacted; and 2) which provider was primarily thought to be 
responsible for re-contacting patients.  
   2.3.3.3 Patient and Physician Comparisons. A chi-square analysis was performed 
between patient and physician responses to the question regarding which provider is 
primarily responsible for updating patients to assess for statistically significant 
differences between the two groups. The response from each participant was assigned to 
one of five categories: genetic counselor, physician, a shared responsibility, patient, or 
unsure. Response frequencies for each of the five categories were recorded and 





   2.4.1 Patients. A total of 73 patients were invited to participate in the study. Eight 
participants completed and returned the questionnaire, yielding an 11% response rate. 
The majority of participants were female. Ages ranged from the 18-29 group to 70 years 
or older. Patients were referred to cancer genetic counseling for a personal and/or a 
family history of cancer, and referral sources came from a variety medical specialists, as 
well as one self-referral. For specific information on demographics, refer to Table 2.1.  
All eight participants reported a desire to be contacted in the future regarding 
updates to the components of genetic testing and counseling discussed during their 
genetic counseling appointment. Patients were asked how frequently and for how many 
years following their initial appointment they desired to be updated with relevant 
information. When asked about the preferred frequency, 38% (n = 3) of patients indicated 
a desire to be update every six months and 63% (n = 5) stated a desire to be updated once 
a year. For the most part, they were similarly divided about the time period in which they 
desired updates, with 50% (n = 4) stating they desired to be kept updated for one year 
following their initial appointment and 38% (n = 3) indicating they desired updates for 
ten years. The remaining participant (n = 1) indicated a desire to be updated for five years 
following her initial appointment with a genetic counselor.  
Responses to these questions were also compared between patients with a 
personal history of cancer (n = 3) and those who had never been diagnosed (n = 5). The 
small sample size limited exploration through chi-square analysis, but descriptive 
statistics are provided. The affected group was evenly divided between a desire to be 
contacted for a time period of either one, five, or ten years following their initial 
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appointment. In the unaffected group, 60% (n = 3) said they desired contact for one year 
following their initial appointment while 40% (n = 2) said they desired updates for a 
period of ten years. When asked about the desired frequency, 33% (n = 1) of the affected 
patients and 40% (n = 2) of unaffected patients indicated an update frequency of every 
six months. Among those who stated a desire for updates once a year, 67% (n = 2) were 
affected and 60% (n = 3) were unaffected. See Figure 2.1 and Figure 2.2.  
Seven of eight patient participants, or 88%, believed the duty to keep patients 
informed fell primarily on the genetic counselor. The participant that did not select the 
genetic counselor as the responsible provider stated any knowledgeable person was an 
acceptable source of new information. When asked about maintaining the patient-
provider relationship, all participants stated they preferred the healthcare provider to 
initiate contact with updates, instead of the patients contacting the provider themselves to 
inquire about new information. The preferred methods of notification by participants 
included phone call (n = 4), letter (n = 3), and email (n = 1). None of the participants 
indicated they desired to be updated by follow-up genetic counseling appointments or 
during appointments at high-risk clinics.  
Seven of eight patient participants, or 88%, indicated they either agreed or 
strongly agreed with being updated when a newer diagnostic test becomes available, and 
when changes in cancer risk, test result status, or management guidelines occur. One 
participant selected strongly disagree to all of these questions. For the statements on 
updates to insurance guidelines and consenting at the initial appointment to future 
updates, 75% (n = 6) of participants either agreed or strongly agreed. The question 
participants agreed with least often pertained to being contacted on a regular basis to 
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provide updates on personal and/or family history. Thirty-eight percent (n = 3) of 
participants indicated they disagreed or strongly disagreed with this question while 63% 
(n = 5) either agreed or strongly agreed. Participants’ responses to all of these questions 
are shown in Table 2.2.  
   2.4.2 Physicians. A total of 44 physician questionnaires were completed and returned. 
Of these questionnaires, two were omitted because they were completed by someone 
other than a physician, leaving a total of 42 physicians who participated in the study. The 
majority of physicians specialized in either OB/Gyn or surgery. Table 2.3 provides the 
physician demographics for the participants enrolled in the study. 
 Of the physicians surveyed in this study, 83% (n = 37) indicated they had referred 
patients to cancer genetic counseling at some point. The 17% (n = 7) of physicians who 
indicated they had never referred to genetic counseling included two pathologists, two 
out of the three radiologists, and one each from surgery, primary care, and OB/Gyn.  
Physicians were asked whether or not patients who were previously seen for 
genetic counseling should be re-contacted when new and relevant genetic information 
becomes available, as well as whose primary responsibility it was to update patients. 
Eighty-six percent (n = 36) stated that patients should be re-contacted with updates, 
although the indications for re-contacting varied. The remaining 14% of participants (n = 
6) who did not explicitly agree with re-contacting patients stated they were uncertain 
about whether or not re-contacting should occur. None of the participants indicated that 
patients should not be re-contacted when new information becomes available. The most 
frequent responses to whose primary responsibility it is to keep patients updated were 
genetic counselors (n = 16), referring physician (n = 10), and a shared responsibility 
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between these two providers (n = 9). See Table 2.4 below for specific information on 
physicians’ responses to these questions.  
Physician participants were asked whether or not they had ever updated patients 
with new information, and 67% (n = 28) indicated they had while 33% (n = 14) 
participants had not. Among those who had never re-contacted patients were three 
surgeons, two pathologists, two radiologists, six OB/Gyns, and one family medicine 
physician.  
   2.4.3 Patient and Physician Comparisons. Both the patient and physician groups 
were asked which provider was responsible for re-contacting patients with updated 
information. Patient and physician responses to this question are shown in Figure 2.1.  
While 88% (n = 7) of patient participants reported they expected updates to come from 
the genetic counselor, only 38% (n = 16) of physicians indicated the genetic counselor as 
the provider primarily responsible for re-contacting. Using chi-square analysis, 
comparison of patient responses to physician responses did not appear to be statistically 
significant, p = .139, but we cannot confirm this due to low patient sample size.  
Physician responses regarding whose primary responsibility it is to update 
patients with new information were further categorized by specialty. Physicians in the 
following specialties more frequently indicated genetic counselors as the sole responsible 
provider: oncologists, surgeons, family medicine/primary care physicians, and 
radiologists. See Table 2.5 for more details.  
2.5 Discussion  
In this study we explored patient and physician opinions on which circumstances 
warrant re-contacting and who is the primary party responsible for providing new 
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information as it becomes available. We also explored the method of re-contacting 
preferred by patients.  
   2.5.1 Patient Responses. The patient group had a low response rate, despite the fact 
patients seemed interested when informed of the study. It is possible some patients 
intended to complete the questionnaire but did not get around to it. Additionally, it is 
possible that patients who answered “no” to the first question decided not to return the 
survey. The first question asked if they would like to be contacted in the future regarding 
updates to the components of genetic testing and counseling that were discussed. If they 
selected “no,” they were asked to stop the survey. It is possible these patients did not 
return the questionnaire because they believed their answer made them ineligible to 
participate.  
All eight patients who participated in the study stated they wished to be re-
contacted in the future regarding updates to the components of genetic testing and 
counseling that were discussed at their appointment. The majority (n = 6) indicated they 
would be open to discussing their preference for future contact with the provider at their 
initial session. However, attaining consent for future, long-term contact is not a current 
standard of practice. A recent study which surveyed genetics providers in the United 
Kingdom found the majority did not routinely acquire permission to re-contact, citing a 
lack of resources to offer this service and concerns about raising the expectations of 
patients (Carrieri et al., 2016). While re-contact by a genetics provider seems to be 
preferred by patients, it is not currently widely done and may not be a practical task. One 
strategy for assisting in the practicality aspect may be developing technology, perhaps 
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based in an electronic medical record, to overcome these barriers traditionally associated 
with re-contacting patients.  
The majority of participants in this study either agreed or strongly agreed with 
being updated for all the circumstances provided on the questionnaire. The circumstances 
participants responded to most favorably included being re-contacted with updates 
pertaining to the availability of newer diagnostic tests, changes in lifetime cancer risk 
based on new research, updates to test results, and changes in management guidelines 
such as how often to be screened and surgery recommendations. These circumstances 
were also listed among the most common reasons for re-contacting by genetics providers 
since these reasons were viewed as clinically actionable (Carrieri et al., 2016). It is likely 
that our patients also felt re-contact is best served by items that may have immediate 
effect on their medical management which was likely thoroughly discussed as part of the 
genetic counseling they received.  
The question participants most strongly disagreed with pertained to the desire to 
be re-contacted on a regular basis to update providers to any changes in their own or their 
family’s health. Interestingly, 75% (n = 6) of participants stated they desired to be re-
contacted if insurance changed in a way that would allow for additional testing options 
that were unavailable at the time of their initial appointment. Even if guidelines for 
insurance do not change, updating the clinic with additional information on family 
members’ medical histories or on newly diagnosed cancers is one way to potentially 
qualify for additional testing. It is possible that patients might not realize the importance 
of informing providers of such information. The National Society of Genetic Counselors 
(NSGC) notes in a position statement, “Collection and annual review of the FHH [Family 
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Health History] allows for risk assessment and can aid in diagnosis, decisions about 
health care, screening, genetic and other test selection, and interpretation of test results, in 
addition to the identification of at-risk relatives” (NSGC, n.d.)  Patients need to be aware 
that changes in personal and family history can be a clinically actionable item. Perhaps, 
there is a role for genetic counselors and other health professionals in calling attention to 
this important fact. Another explanation could be that patients perceive updates to history 
as only potentially leading to a clinically actionable conclusion. Together, these results 
suggest patients desire highly personalized updates that are clinically actionable at the 
time of the update and are less interested in re-contact for other reasons.  
Although all participants stated a desire for future updates, one participant 
strongly disagreed to being contacted for all the circumstances provided on the 
questionnaire. One possible explanation for this may have been the situations in which 
she would have desired re-contacting were not included on the questionnaire. It is also 
possible that she agreed with the notion of re-contacting patients in a general sense but 
did feel not this was relevant in her particular circumstance. This patient was between the 
age of 50-59 years and was referred to genetic counseling by her primary care physician 
based on her family history of breast cancer. An opportunity for an open-ended response 
might have provided more insight into her preferences. 
Participants in this study indicated a desire to be re-contacted for a time period 
ranging from one to ten years following their initial genetic counseling appointment. The 
time period in which patients wish to be followed may be influenced by personal history. 
We found participants who were unaffected were less likely to indicate a desire for 
updates for further out than a year following their initial appointment. However, small 
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sample size limited exploration of this question, and we cannot claim any statistically 
significant results. Unfortunately, this study was unable to weigh the impact of a positive 
or negative test result on desired time period for future contact. This might be an area for 
future study. 
A frequency of updates once every six months or one year was most appropriate 
according to participants. No one desired less frequent contact such as once every five or 
ten years. Two of the three participants in this study who stated they wanted updates as 
often as every six months were unaffected. A qualitative study surrounding why they 
wanted updates so frequently would be an informative supplement to our study. For 
unaffected patients, frequency of contact may be associated with closeness to an affected 
relative. For affected patients, the amount of time since cancer diagnosis may 
significantly influence the frequency with which they desire updates. For example, 
patients in the middle of treatment may desire more frequent updates due to perceived or 
actual relevance to their treatment and ongoing care.  
Participants had a strong preference against in-person updates compared to 
updates via phone, email, or letter. No one indicated a desire to be updated during a 
follow-up genetic counseling appointment or during a high-risk cancer surveillance 
appointment. Perhaps participants did not want to be updated at a future genetic 
counseling appointment because it is inconvenient to schedule another appointment 
amongst busy lives. It is less clear as to why patients would not desire updates during 
regular high-risk cancer surveillance appointments. It is possible patients prefer to receive 
this information from the genetic counselor instead of the provider at the high-risk clinic. 
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It is also possible that many of our surveyed patients do not participate in a high-risk 
clinic, and thus, they do not see the relevance in this answer.  
When asked whose primary responsibility it was to update patients with new 
information, participants were given the choice between genetic counselor, the physician 
who referred them to genetic counseling, or an option to provide their own answer. All 
patients agreed genetic counselors play an important role in updating patients, and all but 
one stated they expected updates to come from the genetic counselor. For the two 
participants referred by surgeons, it would make sense that they would prefer to be re-
contacted by the genetic counselor instead of the referring physician since they would be 
unlikely to have an ongoing relationship with their surgeon. However, even when 
participants were referred by providers in which they are likely to have an ongoing 
relationship with (e.g., primary care physician, OB/Gyn, and gastroenterologist), the 
majority of patients preferred to be updated by the genetics provider over the physician. 
This could indicate trust in genetics professional, and a preference for specialized 
individuals. 
   2.5.2 Physician Responses. The majority of physicians in this study reported they had 
referred patients to a cancer genetic counselor at some point. However, it is possible 
those who referred may have been more likely to respond to the survey than those who 
have not referred. Nevertheless, this may still suggest the physicians included in this 
study value genetic counselors as non-physician medical specialists.  
It was not surprising that both pathologists in this study were among the seven 
physicians who indicated they had never referred to cancer genetic counseling since 
pathologists typically do not have direct interaction with patients. It is also less common 
 
 38
for radiologists to refer even though they are involved in cancer care, as the referral 
usually comes from a specialist more involved in directing the patient’s management 
following genetic testing. Surgeons and OB/Gyns are common sources of referrals. It is 
possible the surgeon that had never referred to genetic counseling in this study was a 
general surgeon and did not specialize in cancer care or was a surgeon new to practice. 
Additionally, it is within a physician’s scope of practice to order genetic testing, so it is 
also possible the physicians that had never referred were ordering testing in their clinic 
instead of referring. It is unknown whether the genetics knowledge or awareness of the 
surveyed physicians had an impact on their referral patterns. 
Overall, physicians in this study believed patients should be re-contacted when 
new and relevant genetic information becomes available and that it is the responsibility of 
the genetic counselor, referring physician, or a shared responsibility between these two 
providers. Consistent with their responses, most physicians stated they had experience 
with updating patients. However, the extent of these updates is unknown. The study 
surveying genetics providers in the United Kingdom found the majority of participants 
had re-contacted patients, although fewer claimed to have done so on a regular basis 
(Carrieri et al., 2016).  
In our study, 33% (n = 14) of physicians, including three surgeons, two 
pathologists, six OB/Gyns, and one family medicine physician had never re-contacted 
patients. Again, it is not surprising that the surgeons and pathologists indicated they had 
never updated patients, since surgeons do not have an ongoing relationship with patients 
and pathologists may not have any patient interaction. It is more surprising that 29% of 
the OB/Gyns that were surveyed claimed to have never updated patients, while 71% of 
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physicians in this specialty indicated that patients should be updated. Additionally, one of 
the OB/Gyns and one of the surgeons included in this group of physicians who had never 
re-contacted patients also stated that the provider responsible for updating patients was 
the referring physician. Both of these physicians indicated they had referred to cancer 
genetic counseling at some point. It is possible these two physicians had never considered 
the duty to re-contact prior to participating in the study, but this disconnect warrants 
further investigation.   
    2.5.3 Patient and Physician Comparisons. All patients and the majority of physicians 
surveyed indicated that patients should be updated when there is new information. Both 
patients and physicians assigned a high level of responsibility to the providers for 
updating patients. Eighty-six percent of physicians assigned this duty solely to providers, 
while 5% claimed the responsibility should be shared between providers and patient. 
Only 2% (n = 1) stated it was the patient’s responsibility to inquire about updates.  
 We were interested in comparing the percentage of patients who indicated genetic 
counselors as the provider primarily responsible for re-contacting patients to the 
percentage of physicians indicating likewise. All patient participants indicated a desire 
for the genetic counselor to be involved, either solely or as a shared responsibility. Some 
of the physician participants (n = 11) indicated the sole responsibility was on the 
physician. A small patient sample size prevented us from demonstrating that our 
responses were statistically significant, although it does not appear to be trending in this 




The ACMG (1999) policy statement regarding the duty to re-contact genetics 
patients states there is a shared responsibility between genetics service providers, other 
healthcare professionals, and patients; however, the statement highlights the primary care 
provider as an important liaison between the patient and the recommendations of the 
genetic provider. Through their survey of physician and PhD geneticists and genetic 
counselors, Fitzpatrick et al. (1999) concluded that there is a shared responsibility 
between providers and patients to remain knowledgeable of updates. The differences 
between their participant population and that of this study may explain the discrepancy 
between findings in this and Fitzpatrick et al.’s (1999) study, since we surveyed a variety 
of physician types and did not limit our participants to genetic service providers. 
Both the ACMG policy and the Fitzpatrick et al. (1999) study support a shared 
responsibility, acknowledging that physicians need to be providing regular updates to the 
patients. Combined with the feelings of our physicians in the study, we can point out the 
potential discrepancy between patients’ feelings and that of their providers. The patients 
surveyed in this study suggested more interest in being updated by their genetic providers 
whereas physicians placed less responsibility on the genetics providers. 
Initial data from our small patient sample supports a previous study conducted by 
Griffin et al. (2007) which found patients desired a longitudinal relationship with their 
providers and to be re-contacted when advancements in cancer genetic medicine 
occurred. Participants also stated it was the healthcare provider’s responsibility to keep 
patients informed, with the genetics provider being most frequently selected as the 
provider expected to update patients. 
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Although physician participants in this study assigned a high level of 
responsibility to the provider for updating patients, there was no consistency among 
physicians as to which provider this responsibility fell upon. If all the providers involved 
in the care of a particular patient assume updates are being provided by another 
professional, then the patient may inadvertently receive no updates from any of his or her 
providers.  
Study Limitations 
Small patient participant sample size limited the types of quantitative analyses that could 
be performed and limited the statistical power. Low response rate could have been the 
result of confusion surrounding the first question where patients were asked to stop the 
survey if they did not wish to be contacted in the future regarding updates to the 
components of genetic testing and counseling discussed. If this were indeed the case, our 
population could be skewed towards those who desire re-contacting, and therefore be a 
misrepresentation of the larger cancer genetics patient population. Clarification of this 
question would be needed in the future. One possible avenue would involve collecting 
questionnaires while still in the clinic rather than by mail. We would also like more 
information across physician specialties.  
Future Research 
Qualitative studies, and even longitudinal quantitative studies, would be of great value to 
explore different factors that may potentially influence a patient’s desire to be re-
contacted in the future with updated information. Some specific areas of future 
exploration include how an individual’s personal history of cancer, or lack there of, 
affected their desire to be re-contacted. This could also be explored in the context of 
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individuals or families with negative test results versus those with positive or uncertain 
results. A next step for this study could include patient focus groups to refine some of the 
questions based on the data collected from this study. We would also like to explore what 
type of updated information physicians are presenting to patients. This could determine 
the level of involvement required by genetic counselors when considering re-contacting 
patients. 
2.6 Conclusions 
This study has implications for the field of genetic counseling, as well as for other 
professions involved in cancer treatment, high-risk cancer surveillance programs, and the 
longitudinal care of patients. It has helped shed light on the expectations of individuals 
undergoing genetic counseling and testing for hereditary cancer conditions regarding 
their desire to remain informed of advancements in patient care. Similar to findings in 
previous studies, we found that patients desire highly personalized updates that are 
perceived as being clinically actionable and place the responsibility of acquiring updated 
knowledge primarily on the genetics provider. Likewise, we found physicians in 
specialties that commonly refer to cancer genetic counseling believe patients should be 
kept informed, and place the responsibility of updating on healthcare providers in 
general. However, there is no consensus on which providers are responsible for fulfilling 
this duty. Furthermore, the only guidelines that currently exist which attempt to address 
this issue may be outdated or not common knowledge among providers following the 
rapid advancements, accessibility, and uptake of genetic testing. Our study provides some 
initial, albeit limited, support of an update to these guidelines, considering our patients’ 
point of view.  
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Table 2.1 Patient Demographics (N = 8) 
Variable n Response (%) 
Age 1 18-29 (13%) 
 1 30-39 (13%) 
 1 40-49 (13%) 
 2 50-59 (25%) 
 2 60-69 (25%) 
 1 70 or older (13%) 
    
Sex 7 Female (88%) 
 1 Male (13%) 
    
Cancer Status 3 Affected (38%) 
 5 Unaffected (63%) 
    
Referring Physician 1 Oncologist (13%) 
 2 Surgeon (25%) 
 1 Gastroenterologist (13%) 
 1 OB/Gyn (13%) 
 2 Primary Care (25%) 
 0 Radiologist (0%) 
 0 Pathologist (0%) 
 0 Maternal Fetal Medicine (0%) 
 1 Self-referred (13%) 




Table 2.2 Patients’ Level of Agreement with Reasons for Re-contacting (N = 8) 
Statement Patient Responses 
  n (%) 
I would like to be contacted if my genetic testing 
results came back negative (no mutation was 
found), and better testing options become 
available. 
Strongly agree 5 (63%) 
Agree 2 (25%) 
Disagree 0 (0%) 
Strongly disagree 1 (13%) 
    
I would like to be contacted if new research 
indicates there has been a change in my lifetime 
risk for developing cancer. 
Strongly agree 5 (63%) 
Agree 2 (25%) 
Disagree 0 (0%) 
Strongly disagree 1 (13%) 
    
I would like to be contacted if there has been a 
change or update to my test result. 
Strongly agree 6 (75%) 
Agree 1 (13%) 
Disagree 0 (0%) 
Strongly disagree 1 (13%) 
    
I would like to be contacted if there is a change for 
ME in medical management guidelines (i.e. how 
often to be screened, surgery recommendations). 
Strongly agree 6 (75%) 
Agree 1 (13%) 
Disagree 0 (0%) 
Strongly disagree 1 (13%) 
    
I would like to be contacted if there is a change for 
FAMILY MEMBERS in medical management 
guidelines (i.e. how often to be screened, surgery 
recommendations). 
Strongly agree 6 (75%) 
Agree 1 (13%) 
Disagree 0 (0%) 
Strongly disagree 1 (13%) 
    
I would like to be contacted on a regular basis to 
update the office on any changes to either my and 
my family’s health. 
Strongly agree 2 (25%) 
Agree 3 (38%) 
Disagree 1 (13%) 
Strongly disagree 2 (25%) 
    
I would like to be contacted if my insurance 
changes in a way that would allow me to get more 
testing than I could based on today’s insurance 
guidelines. 
Strongly agree 2 (25%) 
Agree 4 (50%) 
Disagree 1 (13%) 
Strongly disagree 1 (13%) 
    
I would like to be asked at my initial genetic 
counseling appointment about whether or not I 
wish to be contacted in the future. 
Strongly agree 3 (38%) 
Agree 3 (38%) 
Disagree 1 (13%) 
Strongly disagree 1 (13%) 
Percentage totals may not equal 100% due to rounding 
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Table 2.3 Physician Demographics (N = 42) 
Variable n Response (%) 
Physician Specialty  4 Oncology (10%) 
 10 Surgery (24%) 
 0 Gastroenterology (0%) 
 21 OB/Gyn (50%) 
 0 Internal Medicine (0%) 
 1 Family Medicine/Primary Care (2%) 
 3 Radiology (7%) 
 2 Pathology (5%) 
 1 Maternal Fetal Medicine (2%) 
 
 
Table 2.4 Provider Responsible for Re-contacting Patients According to Physicians 
in Different Specialties (N = 42)  
 
Variable n Response (%) 
Should patients be re-contacted 
when new information becomes 
available? 
27 Yes to all new information  (64%) 
9 Yes, only when management 
guidelines change 
(21%) 
0 Yes, only when new tests become 
available 
(0%) 
0 No (0%) 
6 Uncertain (14%) 
   
Whose primary responsibility is 
it to keep patients updated? 
16 Genetic counselor/genetics provider (38%) 
10 Referring physician (24%) 
1 Oncologist (2%) 
1 Patient (2%) 
9 Physician and genetic counselor (21%) 
2 Physician, genetic counselor, and 
patient 
(5%) 
3 Unsure (7%) 





Table 2.5 Provider Responsible for Re-contacting Patients (N = 42) 
 Genetic 
Counselor 
Physician Shared Patient Unsure 
Specialty n (%) n (%) n (%) n (%) n (%) 
Oncology 2 50% 2 50% 0 0% 0 0% 0 0% 
Surgery 5 50% 2 20% 3 30% 0 0% 0 0% 




1 100% 0 0% 0 0% 0 0% 0 0% 
Radiology 2 67% 1 33% 0 0% 0 0% 0 0% 
Pathology 0 0% 1 50% 1 50% 0 0% 0 0% 
MFM 0 0% 1 100% 0 0% 0 0% 0 0% 








Figure 2.1 Desired Length of Follow-Up in Affected and Unaffected Participants 




Figure 2.2 Desired Frequency of Updates in Affected and Unaffected Participants 




















Figure 2.1 Person Responsible for Updating Patients 
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Chapter 3: Conclusions 
This study has implications for the field of genetic counseling, as well as for other 
professions involved in cancer treatment, high-risk cancer surveillance programs, and the 
longitudinal care of patients. It has helped shed light on the expectations of individuals 
undergoing genetic counseling and testing for hereditary cancer conditions regarding 
their desire to remain informed of advancements in patient care. Similar to findings in 
previous studies, we found patients desire highly personalized updates that are perceived 
as being clinically actionable, and place the responsibility of acquiring updated 
knowledge primarily on the genetics provider. Likewise, we found physicians in 
specialties that commonly refer to cancer genetic counseling believe patients should be 
kept informed, and place the responsibility of updating on healthcare providers in 
general. However, there is no consensus on which providers are responsible for fulfilling 
this duty. Furthermore, the only guidelines that currently exist which attempt to address 
this issue may be outdated or not common knowledge among providers following the 
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Appendix A: Participant Introductory Letter 
University of South Carolina School of Medicine 
USC Genetic Counseling Program 
 
Dear Potential Participant: 
 
You are invited to participate in a graduate research study focusing on the duty to re-
contact patients who undergo genetic counseling for hereditary cancer syndromes. I am a 
graduate student in the genetic counseling program at the University of South Carolina 
School of Medicine. My research investigates the preferences of patients that have 
undergone genetic counseling. The research involves completing and returning a 
questionnaire. 
 
The questionnaire attempts to measure your interest in being re-contacted, the best 
method for being re-contacted, and whose responsibility it is to re-contact you. If you do 
not wish to answer a certain question, please skip that question and continue with the rest 
of the questionnaire. Completing the questionnaire and stating that you desire to be 
re-contacted does not guarantee that you will be re-contacted in the future. We are 
investigating that possibility with this research study, but do not currently have the ability 
to re-contact all patients with updates. We encourage you to re-contact us with any 
questions about your management or updates to your history. 
 
All responses gathered from the questionnaires will be kept anonymous and confidential. 
You do not need to provide your name, contact information, or any other identifying 
information. We will not attempt to contact you again for this study after you complete 
the questionnaire. The results of this study might be published or presented at academic 
meetings; however, participants will not be identified. 
 
Your participation in this research is voluntary. By completing the questionnaire, you are 
consenting that you have read and understand this information. At any time, you may 
withdraw from the study by not completing the questionnaire. 
 
Thank you for your time and consideration to participate in this survey. Your responses 
may help genetic counselors gain a better understanding of the needs and expectations of 
their patients. If you have any questions regarding this research, you may contact either 
myself or my faculty adviser, Whitney Dobek, MS, CGC, using the contact information 
below.  If you have any questions about your rights as a research participant, you may 




Student Contact Information 
Zoe Siegel, B.S. 
Genetic Counselor Candidate 
University of South Carolina School of 
Medicine 
USC Genetic Counseling Program 
Two Medical Park, Suite 208 







































Thesis Advisor Contact Information 
Whitney Dobek, MS, CGC 
Faculty Adviser 
University of South Carolina School of 
Medicine 
USC Genetic Counseling Program 
Two Medical Park, Suite 208 








Appendix B: Patient Questionnaire 
 
University of South Carolina School of Medicine 
USC Genetic Counseling Program
 
1. Would you like to be contacted in the future regarding updates to the components of 
genetic testing and counseling that were discussed today? 
a) Yes 
b) No (if no, stop survey) 
 
Questions #2-9 concern conditions under which you would or would not like to be 
contacted regarding the components of genetic testing and counseling that were discussed 




Disagree Agree Strongly 
Agree 
2. I would like to be contacted if my genetic 
testing results came back negative (no 
mutation was found), and better testing 









     
3. I would like to be contacted if new 
research indicates there has been a change in 
my lifetime risk for developing cancer.  
1 2 3 4 
     
4. I would like to be contacted if there has 
been a change or update to my test result. 
1 2 3 4 
     
5. I would like to be contacted if there is a 
change for ME in medical management 
guidelines (i.e. how often to be screened, 
surgery recommendations).  
 
1 2 3 4 
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6. I would like to be contacted if there is a 
change FOR FAMILY MEMBERS in 
medical management guidelines (i.e. how 
often to be screened, surgery 
recommendations).  
1 2 3 4 
     
7. I would like to be contacted on a regular 
basis to update the office on any changes to 
either my and my family’s health.  
1 2 3 4 
     
8. I would like to be contacted if my 
insurance changes in a way that would allow 
me to get more testing than I could based on 
today’s insurance guidelines.  
1 2 3 4 
     
9. I would like to be asked at my initial 
genetic counseling appointment about 
whether or not I wish to be contacted in the 
future. 
1 2 3 4 
 
Questions #10-11 refer to how often you prefer to be contacted. Please select one answer 
for each question.  
 
10. How frequently would you prefer to be updated with relevant information (e.g. better 
testing options, management changes, etc.)? 
a)   Every 6 months 
b)   Once a year 
c)   Once every 5 years 
d)   Once every 10 years 
e)   Other: _____________________ 
 
11. For how many years after your initial genetic counseling appointment would you like 
to be updated when new relevant information (e.g. better testing options, management 
changes, etc.) becomes available?  
a) One year following appointment 
b) Two years following appointment 
c) Five years following appointment 
d) Ten years following appointment 




Questions #12-14 refer to methods that might be used to contact you. Please select one 
answer for each question.  
 
12. Who would you expect to contact you with updates to the components of genetic 
testing and counseling discussed today? (Choose one) 
a) The physician that referred you to genetic counseling  
b) Genetic Counselor  
c) Other: _____________________ 
 
13. Which method of notification would you prefer most? (Choose one) 
a) Phone call 
b) Letter 
c) Email 
d) During follow-up genetic counseling appointment 
e) During high-risk clinic appointment 
f) Other: ______________________ 
 
14. Which do you prefer regarding new information discussed in today’s session? 
(Choose one) 
a) You contact your provider to ask about new information as you desire it 
b) Your genetic service provider contacts you when there is new information 




15. Please circle your age range. 
a) 18-29  
b) 30-39 
c) 40-49   
d) 50-59 
e) 60-69   
f) 70 or older 
 
16. Please circle your sex. 






17. Please indicate why you were referred to genetic counseling. (CIRCLE ALL that 
apply) 
a) Breast cancer diagnosis 
b) Family history of breast cancer 
c) Colon cancer diagnosis 
d) Family history of colorectal cancer 
e) Known hereditary cancer gene mutation in family 
f) Other: _____________________________ 
 








d) Primary care physician/family doctor 
e) Self referral  









Appendix C: Physician Questionnaire
University of South Carolina School of Medicine 
USC Genetic Counseling Program 
 
You are invited to participate in a graduate research study focusing on the duty to re-
contact patients who undergo genetic counseling for hereditary cancer syndromes.  
 
About the research: I am a graduate student in the genetic counseling program at the 
University of South Carolina School of Medicine. My research investigates how and for 
what reason patients who have undergone genetic counseling would like to be updated 
with new and relevant information. I am also interested in examining whether patient 
opinions are in line with the expectations of their physicians. 
 
Your participation involves completing and returning a questionnaire. Your participation 
in this research is voluntary. By completing the questionnaire, you are consenting that 
you have read and understand this information. Your responses will help genetic 
counselors gain a better understanding of the needs and expectations of their patients.   
 
Thank you for your time and consideration. 
 
 
1. What is your specialty? 
a) Oncologist  
b) Surgeon 
c) Gastroenterologist 
d) OB/GYN  
e) Internal medicine 
f) Family medicine 
g) Other:        
 
2. Have you ever referred a patient for cancer genetic counseling? 
a) Yes   





3. Should patients previously seen for cancer genetic counseling be re-contacted when 
new and relevant genetic information is available (e.g. management guidelines change, 
new testing becomes available, etc.)? 
a) Yes to all 
b) Yes, management changes only 
c) Yes, new testing only   
d) No  
e) Uncertain 
 
4. Whose primary responsibility is it to keep patients updated on new genetic 
information? 
a) Genetic counselor/genetics provider   
b) Physician who referred to genetics     
c) Patient 
d) No one; the patient should not be updated 
e) Other:      
 
5. Have you ever informed patients when there is new and relevant genetic information 
available (e.g. management guidelines change, new testing available, etc.)? 
a) Yes   
b) No 
 
